Beyond traditional monitoring of kidney transplant recipients, donor derived-cell free DNA may permit early identification of graft damage.

Medicare now covers Guardant Reveal for monitoring colorectal cancer recurrence after curative therapy. Analyst sees expanded coverage boosting revenue and improving gross margins by year-end. Ready ...

Our comprehensive Epilepsy Program delivers world-class care for epilepsy patients with state-of-the-art techniques and treatment approaches. U of U Health is one of only a few medical centers in the ...

SWIFT-seq uses single-cell sequencing to profile CTCs, offering a noninvasive alternative to bone marrow biopsies for MM diagnosis and monitoring. The method provides comprehensive genomic and ...

As part of routine care in our six-hospital health system (which includes more than 500 outpatient practices), adults in our electronic health record with Covid-19 infection — as determined by their ...

Oncocyte progresses towards FDA authorization for its transplant rejection monitoring test, with top U.S. centers participating in the trial. Oncocyte Corp. has made significant progress in preparing ...

New Guardant Reveal offering provides oncologists with tissue-free solution to monitor treatment response and detect early disease progression with unprecedented speed and sensitivity Reveal is ...

A simple test developed at Washington State University could eventually allow astronauts and others in round-the-clock ...